A 30-year-old Japanese woman weighing 35 kg with severe hemochromatosis due to multiple transfusions was referred to our clinic for treatment of severe aplastic anemia (SAA). The patient had heart failure with an ejection fraction of 36% requiring diuretics and a sev- 
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), cyclophosphamide (CY, 1200 mg/m 2 ) and antithymocyte globulin (ATG, 15 mg/kg) followed by allogeneic peripheral blood stem cell transplantation (PBSCT) from her HLA-matched sister. The regimen was well tolerated, and engraftment rapidly occurred without any therapyrelated complications. Chimerism analysis on day 14 after transplant showed reconstitution with 100% donor cells. She no longer needed transfusion after day 23 and has been well in 90% Karnofsky status at 4 months post transplant. The clinical course of this patient indicates that this preparative regimen enables SAA patients with severe organ failure to safely undergo allogeneic stem cell transplantation. Bone Marrow Transplantation (2001) 28, 783-785. Keywords: non-myeloablative stem cell transplantation; aplastic anemia; hemochromatosis Allogeneic BMT from an HLA-identical sibling is a highly effective treatment for patients with severe aplastic anemia (SAA). However, outcome of this treatment can be negatively affected when there is organ damage after multiple transfusions in patients with long-standing SAA. Such damage includes heart failure, liver dysfunction and diabetes mellitus. Multiple transfusions also sensitize SAA patients with alloantigens and place them at high risk of graft rejection. 1 Thus, some heavily transfused patients are ineligible for BMT even when an HLA-identical donor is available.
Use of non-myeloablative preparative regimens is being explored for grafting patients with hematological or nonhematological malignancies not normally considered for allogeneic stem cell transplantation because of poor organ function or advanced age. [2] [3] [4] [5] Compared to conventional preparative regimens for allografting, these regimens produce less toxicity but are more frequently associated with graft rejection. Thus, non-myeloablative regimens have rarely been used for BMT in SAA patients for whom engraftment failure is a particular problem. 6, 7 We describe successful non-myeloablative stem cell transplantation in a SAA patient with heart failure and other severe complications related to multiple transfusions.
Case reports
In August 2000, a 30-year-old Japanese woman with acquired SAA was referred to the Hospital of Hokkaido University School of Medicine. She developed severe pancytopenia in 1980. Her peripheral blood counts at presentation were: WBC 1.6 × 10 9 /l with 47% neutrophils, hemoglobin 6.7 g/dl and platelets 16 × 10 9 /l. Bone marrow biopsy revealed severe hypoplasia. Fanconi anemia was excluded by diepoxybutane testing of peripheral blood lymphocytes. She was diagnosed with SAA and had been treated with high-dose methylpredonisolone, cyclosporine A (CyA) and anabolic steroids, without appreciable effects. For 12 years a large number of transfusions was required to keep her alive; she had been given 400 ml of red blood cells weekly and 20 units of platelet concentrate from an HLA-matched donor as anti-HLA antibodies were present. Due to transfusion-related hemochromatosis with a serum ferritin level of 7476 g/l, she developed cardiac failure requiring furosemide 80 mg p.o. daily and diabetes mellitus was evident from 1999. She frequently required admission to a referring hospital because of severe nosebleeds and infections. A donor search for allogeneic stem cells was carried out just before referral and her sister proved to be Bone Marrow Transplantation HLA-identical. A general work-up on admission revealed an ejection fraction of 36% on echocardiography and chronic HCV hepatitis with a delayed excretion rate (18%) on the indocyanine green (ICG) clearance test. Since antithymocyte globulin (ATG) is ineffective for such longstanding SAA, allogeneic stem cell transplantation from her sister was considered to be the treatment of choice. However, we anticipated that she would not tolerate the standard conditioning regimen, which includes high-dose cyclophosphamide (CY) as her cardiac and liver functions were markedly impaired. Based on a report of an encouraging outcome after non-myeloablative stem cell transplantation for SAA, 7 we decided to treat her using a non-myeloablative conditioning regimen followed by allogeneic PBSCT. Prior to this treatment, she gave written informed consent, as required and approved by the Committee of Hokkaido University School of Medicine for the Protection of Human Subjects.
She was given 30 mg/m 2 fludarabine monophosphate (Flu), 300 mg/m 2 CY and 3.75 mg/kg rabbit ATG (Thymoglobulin IMTIX, Lyon, France) on days −6 to −3 commencing on 14 September 2000. 7 She received G-CSFmobilized PBSC from her sister on day 0, containing 9.02 × 10 6 /kg CD34 + cells. As GVHD prophylaxis, short-course methotrexate and CyA were administered; continuous i.v. CyA, 1 mg/kg on days −6 to −2, 2 mg/kg on day −1 to day +20 and i. days +3 and +6. Oral CyA, 6 mg/kg, was initiated on day +21 and was continued with dose adjustments depending on serum CyA levels. Engraftment was rapid; a rise in neutrophils to over 0.5 × 10 9 /l, platelets to over 20 × 10 9 /l and reticulocytes to over 50 × 10 9 /l occurred at 12, 23 and 16 days after transplantation, respectively. The final red blood cell transfusion was given on day +13 and platelets on day +22. Her nutrition status was orally maintained throughout the early post-transplant period. Therapy-related complications did not occur and nosebleeds were only transient. PCR analysis of short tandem repeat polymorphism on peripheral blood leukocytes showed reconstitution with 100% donor cells on day 14, 8 and full chimerism has continued since. On day 90, her liver dysfunction worsened due to limited chronic GVHD but improved when the dose of CyA was increased. There was no evidence of cytomegalovirus, adenovirus or EB virus infection. As of day 130 after transplantation, the WBC was 3.8 × 10 9 /l with 58% neutrophils, hemoglobin level 9.1 g/dl and platelets 40 × 10 9 /l without the need for blood transfusions (Figure 1 ).
Discussion
General guidelines for stem cell transplantation include a left ventricular EF exceeding 50-55%. 9, 10 Life-threatening and often fatal cardiac toxicity have occurred in SAA patients conditioned with high-dose CY. This complication can occur even in patients with normal cardiac function on echocardiography. 11 In addition, patients receiving highdose CY need hydration and forced saline diuresis to prevent the urothelial toxicity associated with this conditioning therapy 12 and this hydration may worsen cardiac function when the recipient has heart failure. The non-myeloablative conditioning regimen used for our patient includes 1200 mg/m 2 of CY, approximately one-fifth of the conventional dosage of CY. This relatively low-dose CY never worsened her cardiac function. CY at a dose lower than 200 mg/kg has rarely been given for preconditioning in acquired SAA, probably due to the fear of graft rejection. 13 Our experience indicates that the dose of CY can be reduced to 1200 mg/m 2 for SAA patients with heart failure, without hindering engraftment of donor stem cells.
Graft rejection was another concern after transplantation because she had been sensitized with alloantigens as multiple transfusions had been given and a less intensified regimen was used for preconditioning. With a Flu/CY/ATG regimen, engraftment of donor cells occurred much earlier than we expected and complete chimerism has been sustained. This early engraftment is consistent with the initial observation on two patients conditioned with the same regimen for BMT from unrelated donors. 7 In our patient, the use of PBSC may have further accelerated establishment of complete chimerism.
14 Intensive conditioning regimens, including low-dose (3-5 Gy) total body irradiation (TBI) are required to ensure engraftment of donor stem cells in SAA patients who have been heavily transfused. 15 Given that the dose of CY in our regimen is only one-fifth of the conventional dose, Flu appears to suppress the host-versusgraft reaction more potently than does low-dose TBI. The successful engraftment indicates that the Flu/CY/ATG regimen is sufficiently potent to suppress the host-versus-graft reaction, even in multiply transfused patients.
Our success in treating this patient with the reduced intensity regimen has important implications for the management of SAA patients with impaired organ function due to secondary hemochromatosis. Allogeneic stem cell transplantation has not been considered the treatment of choice for such patients even when an HLA-identical donor is available as the probability of treatment-related death is high. Confirmation of our finding on a larger series of SAA patients will encourage physicians to consider non-myeloablative stem cell transplantation which may eventually improve prognosis of heavily transfused patients with SAA.
